What is the P/E ratio of Neuren Pharmaceuticals 2024?
The Neuren Pharmaceuticals P/E ratio is 18.9.
Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Subscribe for $2 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Overview
Profile
Neuren Pharmaceuticals Company stock price, forecast, news, chart, split, dividend and analysis Neuren Pharmaceuticals ariva, Neuren Pharmaceuticals onvista, Neuren Pharmaceuticals finanzen.net, Neuren Pharmaceuticals aktienfinder, Neuren Pharmaceuticals marketscreener, Neuren Pharmaceuticals marketwatch, Neuren Pharmaceuticals bloomberg, Neuren Pharmaceuticals handelsblatt, Neuren Pharmaceuticals wiwo, Neuren Pharmaceuticals forum
NEU.AX
NZNEUE0001S8
Price
Price
13.19
Today +/-
+0.06
Today %
+0.80 %
TickerNEU.AX
ISINNZNEUE0001S8
P
Neuren Pharmaceuticals stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Neuren Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Neuren Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Neuren Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Neuren Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Neuren Pharmaceuticals Stock Price History
| Date | Neuren Pharmaceuticals Price |
|---|---|
| 10/18/2024 | 13.19 undefined |
| 10/17/2024 | 13.09 undefined |
| 10/16/2024 | 12.78 undefined |
| 10/15/2024 | 13.00 undefined |
| 10/14/2024 | 13.02 undefined |
| 10/11/2024 | 12.93 undefined |
| 10/10/2024 | 13.15 undefined |
| 10/9/2024 | 13.24 undefined |
| 10/8/2024 | 13.56 undefined |
| 10/7/2024 | 14.16 undefined |
| 10/4/2024 | 14.00 undefined |
| 10/3/2024 | 14.57 undefined |
| 10/2/2024 | 15.01 undefined |
| 10/1/2024 | 15.14 undefined |
| 9/30/2024 | 15.13 undefined |
| 9/27/2024 | 15.26 undefined |
| 9/26/2024 | 14.33 undefined |
| 9/25/2024 | 13.84 undefined |
| 9/24/2024 | 13.90 undefined |
| 9/23/2024 | 13.95 undefined |
Neuren Pharmaceuticals Revenue, EBIT, Net Income NZNEUE0001S8 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Neuren Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neuren Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neuren Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Neuren Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Neuren Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Neuren Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neuren Pharmaceuticals’s growth potential.
Neuren Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Neuren Pharmaceuticals Revenue | Neuren Pharmaceuticals EBIT | Neuren Pharmaceuticals Net Income |
|---|---|---|---|
| 2026e | 198.89 M undefined | 160.47 M undefined | 106.86 M undefined |
| 2025e | 173.12 M undefined | 118.76 M undefined | 94.69 M undefined |
| 2024e | 133.33 M undefined | 97.32 M undefined | 88.67 M undefined |
| 2023 | 237.63 M undefined | 204.93 M undefined | 157.08 M undefined |
| 2022 | 15.81 M undefined | -341,000 undefined | 184,000 undefined |
| 2021 | 3.24 M undefined | -8.19 M undefined | -7.79 M undefined |
| 2020 | 864,000 undefined | -8.66 M undefined | -9.19 M undefined |
| 2019 | 389,000 undefined | -10.69 M undefined | -10.82 M undefined |
| 2018 | 13.76 M undefined | 6.03 M undefined | 3.07 M undefined |
| 2017 | 47,000 undefined | -6.03 M undefined | 3.29 M undefined |
| 2016 | 1.49 M undefined | -11.83 M undefined | -12.01 M undefined |
| 2015 | 2.01 M undefined | -15.24 M undefined | -13.4 M undefined |
| 2014 | 3.49 M undefined | -9.16 M undefined | -8.3 M undefined |
| 2013 | 4.99 M undefined | -6.43 M undefined | -10.44 M undefined |
| 2012 | 4.37 M undefined | -4.98 M undefined | -5.02 M undefined |
| 2011 | 3.31 M undefined | -4.99 M undefined | -4.68 M undefined |
| 2010 | 4.85 M undefined | -4.92 M undefined | -5.06 M undefined |
| 2009 | 4.97 M undefined | -40,000 undefined | 100,000 undefined |
| 2008 | 2.41 M undefined | -9.81 M undefined | -15.47 M undefined |
| 2007 | 2.13 M undefined | -12.04 M undefined | -12.11 M undefined |
| 2006 | 1.77 M undefined | -10.17 M undefined | -9.78 M undefined |
| 2005 | 2.58 M undefined | -8.7 M undefined | -8.66 M undefined |
| 2004 | 2.34 M undefined | -5.45 M undefined | -5.56 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.34 M AUD | -5.45 M AUD | -5.56 M AUD |
| 2005 | 2.58 M AUD | -8.7 M AUD | -8.66 M AUD |
| 2006 | 1.77 M AUD | -10.17 M AUD | -9.78 M AUD |
| 2007 | 2.13 M AUD | -12.04 M AUD | -12.11 M AUD |
| 2008 | 2.41 M AUD | -9.81 M AUD | -15.47 M AUD |
| 2009 | 4.97 M AUD | -40,000 AUD | 100,000 AUD |
| 2010 | 4.85 M AUD | -4.92 M AUD | -5.06 M AUD |
| 2011 | 3.31 M AUD | -4.99 M AUD | -4.68 M AUD |
| 2012 | 4.37 M AUD | -4.98 M AUD | -5.02 M AUD |
| 2013 | 4.99 M AUD | -6.43 M AUD | -10.44 M AUD |
| 2014 | 3.49 M AUD | -9.16 M AUD | -8.3 M AUD |
| 2015 | 2.01 M AUD | -15.24 M AUD | -13.4 M AUD |
| 2016 | 1.49 M AUD | -11.83 M AUD | -12.01 M AUD |
| 2017 | 47,000 AUD | -6.03 M AUD | 3.29 M AUD |
| 2018 | 13.76 M AUD | 6.03 M AUD | 3.07 M AUD |
| 2019 | 389,000 AUD | -10.69 M AUD | -10.82 M AUD |
| 2020 | 864,000 AUD | -8.66 M AUD | -9.19 M AUD |
| 2021 | 3.24 M AUD | -8.19 M AUD | -7.79 M AUD |
| 2022 | 15.81 M AUD | -341,000 AUD | 184,000 AUD |
| 2023 | 237.63 M AUD | 204.93 M AUD | 157.08 M AUD |
| 2024e | 133.33 M AUD | 97.32 M AUD | 88.67 M AUD |
| 2025e | 173.12 M AUD | 118.76 M AUD | 94.69 M AUD |
| 2026e | 198.89 M AUD | 160.47 M AUD | 106.86 M AUD |
Neuren Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 2 | 2 | 1 | 2 | 2 | 4 | 4 | 3 | 4 | 4 | 3 | 2 | 1 | 0 | 13 | 0 | 0 | 3 | 15 | 237 | 133 | 173 | 198 |
| - | - | - | -50.00 | 100.00 | - | 100.00 | - | -25.00 | 33.33 | - | -25.00 | -33.33 | -50.00 | - | - | - | - | - | 400.00 | 1,480.00 | -43.88 | 30.08 | 14.45 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -3 | -5 | -8 | -10 | -12 | -9 | 0 | -4 | -4 | -4 | -6 | -9 | -15 | -11 | -6 | 6 | -10 | -8 | -8 | 0 | 204 | 97 | 118 | 160 |
| -150.00 | -250.00 | -400.00 | -1,000.00 | -600.00 | -450.00 | - | -100.00 | -133.33 | -100.00 | -150.00 | -300.00 | -750.00 | -1,100.00 | - | 46.15 | - | - | -266.67 | - | 86.08 | 72.93 | 68.21 | 80.81 |
| -3 | -5 | -8 | -9 | -12 | -15 | 0 | -5 | -4 | -5 | -10 | -8 | -13 | -12 | 3 | 3 | -10 | -9 | -7 | 0 | 157 | 88 | 94 | 106 |
| - | 66.67 | 60.00 | 12.50 | 33.33 | 25.00 | - | - | -20.00 | 25.00 | 100.00 | -20.00 | 62.50 | -7.69 | -125.00 | - | -433.33 | -10.00 | -22.22 | - | - | -43.95 | 6.82 | 12.77 |
| 0.18 | 3.32 | 8.12 | 6.44 | 7.39 | 12.32 | 15.02 | 21.24 | 38.24 | 58.71 | 63.06 | 77.62 | 84.02 | 84.68 | 93.03 | 99.75 | 100.17 | 107.06 | 117.77 | 125.97 | 127.07 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Neuren Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Neuren Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Neuren Pharmaceuticals stock margins NZNEUE0001S8 ·
The Neuren Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neuren Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neuren Pharmaceuticals.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Neuren Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Neuren Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Neuren Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Neuren Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neuren Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neuren Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neuren Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Neuren Pharmaceuticals Margin History
| Neuren Pharmaceuticals Gross margin | Neuren Pharmaceuticals Profit margin | Neuren Pharmaceuticals EBIT margin | Neuren Pharmaceuticals Profit margin |
|---|---|---|---|
| 2026e | 0 % | 80.68 % | 53.73 % |
| 2025e | 0 % | 68.6 % | 54.7 % |
| 2024e | 0 % | 72.99 % | 66.5 % |
| 2023 | 0 % | 86.24 % | 66.1 % |
| 2022 | 0 % | -2.16 % | 1.16 % |
| 2021 | 0 % | -253 % | -240.7 % |
| 2020 | 0 % | -1,002.55 % | -1,064 % |
| 2019 | 0 % | -2,747.3 % | -2,780.46 % |
| 2018 | 0 % | 43.84 % | 22.33 % |
| 2017 | 0 % | -12,821.28 % | 6,995.74 % |
| 2016 | 0 % | -791.77 % | -804.15 % |
| 2015 | 0 % | -759.16 % | -667.18 % |
| 2014 | 0 % | -262.46 % | -237.82 % |
| 2013 | 0 % | -128.86 % | -209.22 % |
| 2012 | 0 % | -113.96 % | -114.87 % |
| 2011 | 0 % | -150.76 % | -141.39 % |
| 2010 | 0 % | -101.44 % | -104.33 % |
| 2009 | 0 % | -0.8 % | 2.01 % |
| 2008 | 0 % | -407.05 % | -641.91 % |
| 2007 | 0 % | -565.26 % | -568.54 % |
| 2006 | 0 % | -574.58 % | -552.54 % |
| 2005 | 0 % | -337.21 % | -335.66 % |
| 2004 | 0 % | -232.91 % | -237.61 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 0 % | -232.91 % | -237.61 % |
| 2005 | 0 % | -337.21 % | -335.66 % |
| 2006 | 0 % | -574.58 % | -552.54 % |
| 2007 | 0 % | -565.26 % | -568.54 % |
| 2008 | 0 % | -407.05 % | -641.91 % |
| 2009 | 0 % | -0.8 % | 2.01 % |
| 2010 | 0 % | -101.44 % | -104.33 % |
| 2011 | 0 % | -150.76 % | -141.39 % |
| 2012 | 0 % | -113.96 % | -114.87 % |
| 2013 | 0 % | -128.86 % | -209.22 % |
| 2014 | 0 % | -262.46 % | -237.82 % |
| 2015 | 0 % | -759.16 % | -667.18 % |
| 2016 | 0 % | -791.77 % | -804.15 % |
| 2017 | 0 % | -12,821.28 % | 6,995.74 % |
| 2018 | 0 % | 43.84 % | 22.33 % |
| 2019 | 0 % | -2,747.3 % | -2,780.46 % |
| 2020 | 0 % | -1,002.55 % | -1,064 % |
| 2021 | 0 % | -253 % | -240.7 % |
| 2022 | 0 % | -2.16 % | 1.16 % |
| 2023 | 0 % | 86.24 % | 66.1 % |
| 2024e | 0 % | 72.99 % | 66.5 % |
| 2025e | 0 % | 68.6 % | 54.7 % |
| 2026e | 0 % | 80.68 % | 53.73 % |
Neuren Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share NZNEUE0001S8 ·
The Neuren Pharmaceuticals earnings per share therefore indicates how much revenue Neuren Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Neuren Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Neuren Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Neuren Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neuren Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Neuren Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Neuren Pharmaceuticals Sales per Share | Neuren Pharmaceuticals EBIT per share | Neuren Pharmaceuticals Earnings per Share |
|---|---|---|---|
| 2026e | 1.56 undefined | 0 undefined | 0.84 undefined |
| 2025e | 1.35 undefined | 0 undefined | 0.74 undefined |
| 2024e | 1.04 undefined | 0 undefined | 0.69 undefined |
| 2023 | 1.87 undefined | 1.61 undefined | 1.24 undefined |
| 2022 | 0.13 undefined | -0 undefined | 0 undefined |
| 2021 | 0.03 undefined | -0.07 undefined | -0.07 undefined |
| 2020 | 0.01 undefined | -0.08 undefined | -0.09 undefined |
| 2019 | 0 undefined | -0.11 undefined | -0.11 undefined |
| 2018 | 0.14 undefined | 0.06 undefined | 0.03 undefined |
| 2017 | 0 undefined | -0.06 undefined | 0.04 undefined |
| 2016 | 0.02 undefined | -0.14 undefined | -0.14 undefined |
| 2015 | 0.02 undefined | -0.18 undefined | -0.16 undefined |
| 2014 | 0.04 undefined | -0.12 undefined | -0.11 undefined |
| 2013 | 0.08 undefined | -0.1 undefined | -0.17 undefined |
| 2012 | 0.07 undefined | -0.08 undefined | -0.09 undefined |
| 2011 | 0.09 undefined | -0.13 undefined | -0.12 undefined |
| 2010 | 0.23 undefined | -0.23 undefined | -0.24 undefined |
| 2009 | 0.33 undefined | -0 undefined | 0.01 undefined |
| 2008 | 0.2 undefined | -0.8 undefined | -1.26 undefined |
| 2007 | 0.29 undefined | -1.63 undefined | -1.64 undefined |
| 2006 | 0.27 undefined | -1.58 undefined | -1.52 undefined |
| 2005 | 0.32 undefined | -1.07 undefined | -1.07 undefined |
| 2004 | 0.7 undefined | -1.64 undefined | -1.67 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 0.7 AUD | -1.64 AUD | -1.67 AUD |
| 2005 | 0.32 AUD | -1.07 AUD | -1.07 AUD |
| 2006 | 0.27 AUD | -1.58 AUD | -1.52 AUD |
| 2007 | 0.29 AUD | -1.63 AUD | -1.64 AUD |
| 2008 | 0.2 AUD | -0.8 AUD | -1.26 AUD |
| 2009 | 0.33 AUD | -0 AUD | 0.01 AUD |
| 2010 | 0.23 AUD | -0.23 AUD | -0.24 AUD |
| 2011 | 0.09 AUD | -0.13 AUD | -0.12 AUD |
| 2012 | 0.07 AUD | -0.08 AUD | -0.09 AUD |
| 2013 | 0.08 AUD | -0.1 AUD | -0.17 AUD |
| 2014 | 0.04 AUD | -0.12 AUD | -0.11 AUD |
| 2015 | 0.02 AUD | -0.18 AUD | -0.16 AUD |
| 2016 | 0.02 AUD | -0.14 AUD | -0.14 AUD |
| 2017 | 0 AUD | -0.06 AUD | 0.04 AUD |
| 2018 | 0.14 AUD | 0.06 AUD | 0.03 AUD |
| 2019 | 0 AUD | -0.11 AUD | -0.11 AUD |
| 2020 | 0.01 AUD | -0.08 AUD | -0.09 AUD |
| 2021 | 0.03 AUD | -0.07 AUD | -0.07 AUD |
| 2022 | 0.13 AUD | -0 AUD | 0 AUD |
| 2023 | 1.87 AUD | 1.61 AUD | 1.24 AUD |
| 2024e | 1.04 AUD | 0 AUD | 0.69 AUD |
| 2025e | 1.35 AUD | 0 AUD | 0.74 AUD |
| 2026e | 1.56 AUD | 0 AUD | 0.84 AUD |
Neuren Pharmaceuticals business model
Neuren Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Neuren Pharmaceuticals Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Neuren Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Neuren Pharmaceuticals shares outstanding NZNEUE0001S8 ·
The number of shares was Neuren Pharmaceuticals in 2023 — This indicates how many shares 127.07 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Neuren Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Neuren Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Neuren Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neuren Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 3.32 M Aktien |
| 2005 | 8.12 M Aktien |
| 2006 | 6.44 M Aktien |
| 2007 | 7.39 M Aktien |
| 2008 | 12.32 M Aktien |
| 2009 | 15.02 M Aktien |
| 2010 | 21.24 M Aktien |
| 2011 | 38.24 M Aktien |
| 2012 | 58.71 M Aktien |
| 2013 | 63.06 M Aktien |
| 2014 | 77.62 M Aktien |
| 2015 | 84.02 M Aktien |
| 2016 | 84.68 M Aktien |
| 2017 | 93.03 M Aktien |
| 2018 | 99.75 M Aktien |
| 2019 | 100.17 M Aktien |
| 2020 | 107.06 M Aktien |
| 2021 | 117.77 M Aktien |
| 2022 | 125.97 M Aktien |
| 2023 | 127.07 M Aktien |
| 2024e | 127.07 M Aktien |
| 2025e | 127.07 M Aktien |
| 2026e | 127.07 M Aktien |
Neuren Pharmaceuticals stock splits
In Neuren Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Neuren Pharmaceuticals.
Neuren Pharmaceuticals latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 6/30/2024 | 0.17 | 0.06 (-64.37 %) | 2024 Q2 |
| 12/31/2023 | 0.99 | 0.83 (-16.05 %) | 2023 Q4 |
| 6/30/2023 | 0.32 | 0.37 (14.93 %) | 2023 Q2 |
| 12/31/2022 | 0.03 | 0.06 (82.11 %) | 2022 Q4 |
| 6/30/2022 | 0.4 | -0.06 (-113.86 %) | 2022 Q2 |
1
Eulerpool ESG Scorecard© for the Neuren Pharmaceuticals stock
Eulerpool World ESG Rating (EESG©)
33/ 100
🌱 Environment
38
👫 Social
10
🏛️ Governance
50
Environment
Scope 1 - Direct Emissions | — |
Scope 2 - Indirect emissions from purchased energy | — |
Scope 3 - Indirect emissions within the value chain | — |
Total CO₂ emissions | — |
| CO₂ reduction strategy | ✅ |
| Coal energy | ❌ |
| Nuclear power | ❌ |
| Animal experiments | ✅ |
| Fur & Leather | — |
| Pesticides | — |
| Palm Oil | — |
| Tobacco | ❌ |
| Genetically modified organisms | ❌ |
| Climate concept | — |
| Sustainable forestry | — |
| Recycling regulations | ❌ |
| Environmentally friendly packaging | ❌ |
| Hazardous substances | ❌ |
| Fuel consumption and efficiency | ❌ |
| Water consumption and efficiency | ❌ |
Social
| Percentage of female employees | — |
| Percentage of women in management | — |
| Percentage of Asian employees | — |
| Share of Asian management | — |
| Percentage of Hispanic/Latino employees | — |
| Hispano/Latino Management share | — |
| Percentage of Black employees | — |
| Black Management Share | — |
| Percentage of white employees | — |
| White Management Share | — |
| Adult content | ❌ |
| Alcohol | ❌ |
| Weapons | — |
| Firearms | ❌ |
| Gambling | ❌ |
| Military contracts | ❌ |
| Human rights concept | ❌ |
| Privacy concept | — |
| Occupational health and safety | ❌ |
| Catholic | ✅ |
Governance (Corporate Governance)
| Environmental reporting | ❌ |
| Stakeholder Engagement | ❌ |
| Call Back Policies | ❌ |
| Antitrust law | ❌ |
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Neuren Pharmaceuticals shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 5.13392 % | Milford Asset Management Ltd. | 6,561,977 | 0 | 3/24/2023 |
| 3.29091 % | Cameron Richard Pty. Ltd. | 4,206,313 | -1,225,947 | 3/24/2023 |
| 2.38101 % | The Vanguard Group, Inc. | 3,043,307 | -6,627 | 3/31/2024 |
| 2.35710 % | Norges Bank Investment Management (NBIM) | 3,012,755 | 2,581,038 | 12/31/2023 |
| 1.92464 % | Stuart Andrew Pty. Ltd. | 2,460,000 | -207,146 | 3/24/2023 |
| 1.88927 % | Scott (Trevor Donald) | 2,414,784 | -1,175,000 | 6/14/2023 |
| 1.76196 % | Vanguard Investments Australia Ltd. | 2,252,067 | 12,823 | 2/29/2024 |
| 1.57257 % | Smithley Super Pty. Ltd. | 2,010,000 | -138,000 | 3/24/2023 |
| 1.47478 % | Linwierik Super Pty. Ltd. | 1,885,000 | -754,643 | 3/24/2023 |
| 1.05734 % | BlackRock Institutional Trust Company, N.A. | 1,351,449 | -2,000 | 3/31/2024 |
1
2
3
4
5
...
8
Neuren Pharmaceuticals Executives and Management Board
Mr. Jonathan Pilcher
Neuren Pharmaceuticals Chief Executive Officer, Managing Director, Executive Director (since 2013)
Compensation 546,338
Mr. Larry Glass
Neuren Pharmaceuticals Chief Science Officer (since 2009)
Compensation 405,000
Mr. Patrick Davies55
Neuren Pharmaceuticals Non-Executive Chairman of the Board
Compensation 125,000
Ms. Dianne Angus
Neuren Pharmaceuticals Non-Executive Independent Director
Compensation 75,000
Dr. Jenny Harry
Neuren Pharmaceuticals Non-Executive Independent Director
Compensation 75,000
1
2
3
Most common questions regarding Neuren Pharmaceuticals
What is the P/S ratio of Neuren Pharmaceuticals 2024?
The Neuren Pharmaceuticals P/S ratio is 12.57.
What is the Quality Investing of Neuren Pharmaceuticals?
The Quality Investing for Neuren Pharmaceuticals is 5/10.
What is the revenue of Neuren Pharmaceuticals 2024?
The expected Neuren Pharmaceuticals revenue is 133.33 M AUD.
How high is the profit of Neuren Pharmaceuticals 2024?
The expected Neuren Pharmaceuticals profit is 88.67 M AUD.
What is the business model of Neuren Pharmaceuticals
No history available for Neuren Pharmaceuticals.
What is the Neuren Pharmaceuticals dividend?
Neuren Pharmaceuticals pays a dividend of 0 AUD distributed over payouts per year.
How often does Neuren Pharmaceuticals pay dividends?
The dividend cannot currently be calculated for Neuren Pharmaceuticals or the company does not pay out a dividend.
What is the Neuren Pharmaceuticals ISIN?
The ISIN of Neuren Pharmaceuticals is NZNEUE0001S8.
What is the Neuren Pharmaceuticals ticker?
The ticker of Neuren Pharmaceuticals is NEU.AX.
How much dividend does Neuren Pharmaceuticals pay?
Over the past 12 months, Neuren Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuren Pharmaceuticals is expected to pay a dividend of 0 AUD.
What is the dividend yield of Neuren Pharmaceuticals?
The current dividend yield of Neuren Pharmaceuticals is .
When does Neuren Pharmaceuticals pay dividends?
Neuren Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neuren Pharmaceuticals?
Neuren Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Neuren Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neuren Pharmaceuticals located?
Neuren Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neuren Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neuren Pharmaceuticals from 10/21/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/21/2024.
When did Neuren Pharmaceuticals pay the last dividend?
The last dividend was paid out on 10/21/2024.
What was the dividend of Neuren Pharmaceuticals in the year 2023?
In the year 2023, Neuren Pharmaceuticals distributed 0 AUD as dividends.
In which currency does Neuren Pharmaceuticals pay out the dividend?
The dividends of Neuren Pharmaceuticals are distributed in AUD.
Neuren Pharmaceuticals stock
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Neuren Pharmaceuticals
Country
Australia 🇦🇺
Currency
AUD
Initial public offering
Feb 3, 2005
GOSIN
Global Open Securities Identification Number
Cusip
Q6634F109
Market capitalization
Quality Investing
5 / 10Details
PEG
1.66
P/E ratio
Forward P/E ratio
19.01
P/S ratio
Forward P/S ratio
9.68
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Neuren Pharmaceuticals Peer Group
Neuren Pharmaceuticals Eulerpool News
Neuren Pharmaceuticals News
Neuren Pharmaceuticals Ticker
| Stock Exchange | Neuren Pharmaceuticals Ticker |
|---|---|
| ASX | NEU.AX |
| PNK | NURPF |
Neuren Pharmaceuticals FIGI
| Neuren Pharmaceuticals Ticker | Neuren Pharmaceuticals FIGI |
|---|---|
| NEU:AU | BBG000CS0G08 |
| NEU:AT | BBG000CS0GB6 |
| NURPF:US | BBG000QP8PX5 |
| NURPF:UV | BBG000QP8YL9 |
| NEU:AH | BBG002F3J261 |
| NEUAUD:EO | BBG01BW9SV64 |
| NEUAUD:X2 | BBG01BW9SV82 |
| NEUAUD:XH | BBG01BW9SVC7 |
| NEUAUD:XF | BBG01BW9SVF4 |
| NEUAUD:XE | BBG01BW9SVH2 |
| NEUAUD:XJ | BBG01BW9SVJ0 |
| NEUAUD:XL | BBG01BW9SVK8 |
| NEUAUD:XG | BBG01BW9SVL7 |
| NEUAUD:XO | BBG01BW9SVM6 |
| NEUAUD:XA | BBG01BW9SVR1 |
| NEUAUD:E1 | BBG01BW9SVS0 |
| NEUAUD:XT | BBG01BW9SVT9 |
| NEUAUD:XW | BBG01BW9SVV6 |
| NEUAUD:XU | BBG01BW9SVW5 |
| NEUAUD:XY | BBG01BW9SVX4 |
| NEUAUD:XV | BBG01BW9SVY3 |
| NEUAUD:XM | BBG01BW9SVZ2 |
| NEUAUD:XQ | BBG01BW9SW08 |
| NEUAUD:XX | BBG01BW9SW17 |
| NEUAUD:XZ | BBG01BW9SW26 |
| NEUAUD:X1 | BBG01BW9SW44 |
| NEUAUD:EU | BBG01BW9SW80 |
All fundamentals about Neuren Pharmaceuticals
Our stock analysis for Neuren Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuren Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Neuren Pharmaceuticals Revenue
- Neuren Pharmaceuticals Net Income
- Neuren Pharmaceuticals P/E
- Neuren Pharmaceuticals P/S
- Neuren Pharmaceuticals EBIT
- Neuren Pharmaceuticals Dividend
- Neuren Pharmaceuticals Stocks
- Neuren Pharmaceuticals Market capitalization
- Neuren Pharmaceuticals Debt
- Neuren Pharmaceuticals Liabilities
- Neuren Pharmaceuticals Equity
- Neuren Pharmaceuticals AAQS
- Neuren Pharmaceuticals Employees
- Neuren Pharmaceuticals ROE
- Neuren Pharmaceuticals ROA
- Neuren Pharmaceuticals ROCE